NCT05354713
Completed
Phase 1
An Clinical Trial to Evaluate the Pharmacokinetics and the Safety of NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers
NVP Healthcare1 site in 1 country58 target enrollmentNovember 5, 2022
ConditionsHealthy Volunteers
Overview
- Phase
- Phase 1
- Intervention
- NVP-1805
- Conditions
- Healthy Volunteers
- Sponsor
- NVP Healthcare
- Enrollment
- 58
- Locations
- 1
- Primary Endpoint
- NVP-1805's Pharmacokinetics of plasma
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2
Detailed Description
Evaluate pharmacokinetics and safety of NVP-1805 compared to coadministration of NVP-1805-R1 with NVP-1805-R2
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy adult subjects who signed informed consent
- •BMI of \>18.0 kg/m2 and \<30.0 kg/m2 subject, weight more than 50kg(45 kg or more for woman)
Exclusion Criteria
- •Subjects participated in another clinical trial within 6 months prior to administration of the study drug
- •Inadequate subject for the clinical trial by the investigator's decision
- •Subjects participated in another clinical trial within 6 months prior to administration of the study drug
Arms & Interventions
NVP-1805
orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
Intervention: NVP-1805
NVP-1805-R1 and NVP-1805-R2
orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
Intervention: NVP-1805-R1 and NVP-1805-R2
Outcomes
Primary Outcomes
NVP-1805's Pharmacokinetics of plasma
Time Frame: 0hours - 72hours
AUCt
Pharmacokinetics of plasma
Time Frame: 0hours - 72hours
Cmax
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2HealthyNCT04780386NVP Healthcare58
Completed
Phase 1
NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult VolunteersHealthy VolunteersNCT04905342NVP Healthcare58
Completed
Phase 1
Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and EzetimibeDyslipidemiaNCT02029625NVP Healthcare41
Completed
Phase 1
A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402HealthyNCT02897726NVP Healthcare38
Completed
Phase 1
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2HealthyNCT03802526NVP Healthcare37